top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

397.77 -2.94 (-0.73%)
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 1.7% in the morning session after the U.S. Food and Drug Administration granted ... 
Via StockStory
News headline image
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
From Natera, Inc.
Via Business Wire
News headline image
3 Market-Beating Stocks with Competitive Advantages
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
News headline image
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
From Natera, Inc.
Via Business Wire
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
2 Growth Stocks to Stash and 1 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
1 Unprofitable Stock to Target This Week and 2 We Question
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar
Check out the companies making headlines yesterday: AutoZone (NYSE:AZO): Auto parts and accessories retailer AutoZone (NYSE:AZO) rose by 6.1% on Tuesday afte... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Natera (NTRA) Stock Soaring Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceu... 
Via StockStory
News headline image
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera CEO Steven Chapman Sells 1,698 Shares for $545,000 ↗
The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
From Natera, Inc.
Via Business Wire
News headline image
This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗
The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those. 
Via The Motley Fool
News headline image
3 Reasons Investors Love Natera (NTRA)
What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This ... 
Via StockStory
News headline image
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) ↗
His largest position today is a bet on genomics. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of... 
Via Benzinga
News headline image
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
From Natera, Inc.
Via Business Wire
News headline image
3 Momentum Stocks to Own for Decades
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
News headline image
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? ↗
The billionaire has good reasons to like this genetic testing leader. 
Via The Motley Fool
News headline image
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
From Natera, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either. ↗
Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks. 
Via The Motley Fool
News headline image
3 Large-Cap Stocks Worth Investigating
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
News headline image
Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story? ↗
The hedge fund legend has bet much of the family office on this one diagnostics company. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth Today ↗
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized basis producing an average annual return of 40.99%. Currently, Natera has a market capitalization of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page